Charles River Laboratories and Autobahn Labs Announce Collaborative Program to Accelerate Academic Drug Discovery
24 Juillet 2024 - 2:00PM
Business Wire
- Agreement establishes Charles River as the preferred partner
for Autobahn Labs, leveraging drug discovery and development
capabilities to accelerate the translation of academic discoveries
into novel therapeutics
- Under the agreement, Charles River will make an equity
investment in Autobahn Labs
- Justin Bryans, Chief Scientific Officer, Discovery at Charles
River, named to Autobahn’s Board of Directors
Charles River Laboratories International, Inc. (NYSE: CRL) and
Autobahn Labs, a Samsara BioCapital-backed virtual accelerator for
academic biotech, today announced a collaborative relationship that
establishes Charles River as the preferred research partner to
support Autobahn’s growing pipeline of early-stage, preclinical
therapeutics’ programs. This agreement will grant Autobahn
preferred access to Charles River’s industry-standard,
state-of-the-art drug discovery and development capabilities. The
purpose of the partnership is to accelerate the advancement of
novel academic science into transformational new therapies across
diverse therapeutic modalities and disease areas.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240724246400/en/
Under the terms of the agreement, Charles River has made an
investment in Autobahn Labs, joining a fundraising round led by
Autobahn’s founding investor, Samsara BioCapital. Proceeds from the
raise and partnership with Charles River will enable Autobahn to
expand the number of partnerships with top-tier academic
institutions, advance lead preclinical programs, and identify new
opportunities for therapeutics development. In conjunction with the
funding, Justin Bryans, Chief Scientific Officer, Discovery for
Charles River, has joined Autobahn’s Board of Directors.
“I am looking forward to partnering with the Autobahn Labs team
as they develop preclinical therapeutics programs,” said Justin
Bryans, Chief Scientific Officer, Discovery, Charles River. “We
expect our combined expertise will help progress drug discovery and
development programs, ultimately delivering critical therapeutics
to patients.”
“We are excited for Charles River to join Samsara BioCapital as
an investor and partner in Autobahn’s mission to translate the best
of academic biotech,” said Brendan O’Leary, CEO of Autobahn Labs.
“Combining Charles River’s industry-leading drug discovery and
development capabilities with Autobahn’s deal sourcing and venture
creation expertise will allow us to efficiently de-risk academic
research with significant therapeutic potential, from novel concept
to preclinical drug candidate.”
About Autobahn Labs Autobahn Labs is a new model for
early-stage drug discovery and development, partnering with leading
research institutions to accelerate the advancement of novel
science to deliver transformational new therapies for patients.
Founded in 2019 by Samsara BioCapital, we invest intellectual,
financial and physical capital, applying our proven drug discovery
framework to efficiently move projects from therapeutic hypothesis
to novel drug candidates. For more information, visit
www.autobahn-labs.com.
About Charles River Charles River provides essential
products and services to help pharmaceutical and biotechnology
companies, government agencies and leading academic institutions
around the globe accelerate their research and drug development
efforts. Our dedicated employees are focused on providing clients
with exactly what they need to improve and expedite the discovery,
early-stage development and safe manufacture of new therapies for
the patients who need them. To learn more about our unique
portfolio and breadth of services, visit www.criver.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240724246400/en/
Charles River Investor Contact: Todd Spencer Corporate
Vice President, Investor Relations 781.222.6455
todd.spencer@crl.com
Charles River Media Contact: Amy Cianciaruso Corporate
Vice President, Chief Communications Officer 781.222.6168
amy.cianciaruso@crl.com
Charles River Laboratories (NYSE:CRL)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Charles River Laboratories (NYSE:CRL)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025
